



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448

FILING MEETING SUMMARY

Date and Time: December 12, 2011 3:00 – 4:00 pm
Location: WOC2 – Room 2330
Call-In Information: **Toll-Free Number:** -----(b)(4)-----
Passcode: ---(b)(4)---
STN #: 125408/0
Supplement Type: Original BLA submission
Sponsor: Novartis Vaccines and Diagnostics Inc.
Product: Optaflu, Influenza Vaccine (MDCK cells)
Signed:

CBER/FDA Invitees

COMMITTEE MEMBERS:

| <u>Name</u> | <u>Role</u> | <u>Division</u> | <u>Attended</u> |
|---------------------------|----------------------------------|-----------------|-----------------|
| Timothy Nelle, Ph.D. | Chair | DVRPA/OVRR | Yes |
| Melisse Baylor, M.D. | Clinical Reviewer | DVRPA/OVRR | Yes |
| Nabil Al-Humadi, Ph.D. | Toxicology Reviewer | DVRPA/OVRR | |
| Tammy Massie, Ph.D. | Statistical Reviewer, Clinical | DB/VEB/OBE | Yes |
| Damon Green, M.D. | Epidemiology Reviewer | DE/OBE | Yes |
| Lihan Yan, Ph.D. | Statistical Reviewer, Bioassay | DB/VEB/OBE | Yes |
| Rajesh Gupta, Ph.D. | CMC Reviewer, Analytical Methods | DBSQC/OCBQ | Yes |
| Karen Campbell | Lot Release | DBSQC/OCBQ | Yes |
| Zhiping Ye, Ph.D. | Product Reviewer | DVP/OVRR | Yes |
| Haruhiko Murata | Product Reviewer | DVP/OVRR | Yes |
| Xianghong Jing | Product Reviewer | DVP/OVRR | Yes |
| Pankaj Amin | Facility Reviewer | DMPQ/OCBQ | Yes |
| Mohammad Heidarani, Ph.D. | Facility Reviewer | DMPQ/OCBQ | Yes |
| Anthony Hawkins | Bioresearch Monitoring Reviewer | DIS/BMB/OCBQ | Yes |
| Maryann Gallagher | Labeling Reviewer | DCM/APLB/OCBQ | Yes |
| LT David Schwab | Electronic Integrity Reviewer | DVRPA/OVRR | |
| Brenda Baldwin, Ph.D. | Regulatory Project Manager | DVRPA/OVRR | Yes |
| Timothy Fritz, Ph.D. | Regulatory Project Manager | DVRPA/OVRR | Yes |

CBER/FDA Invitees:

| | | | |
|----------------------------|-----------------------------|------------|-----|
| Elizabeth Sutkowski, Ph.D. | Branch Chief | DVRPA/OVRR | Yes |
| Douglas Pratt, M.D. | Supervisory Medical Officer | DVRPA/OVRR | |
| Martin Green, Ph.D. | Supervisory Toxicologist | DVRPA/OVRR | |
| Rakesh Pandey, Ph.D. | Branch Chief | DVRPA/OVRR | |
| Amelia Horne, Ph.D. | Supervisory Mathematician | DB/VEB/OBE | |

| | | | |
|--------------------------|-------------------------------------|---------------|-----|
| Tsai-Lien Lin, Ph.D. | Lead Mathematician Statistician | DB/VEB/OBE | |
| William McCormick, Ph.D. | Division Director | DPQ/OCBQ | Yes |
| Jerry Weir, Ph.D. | Division Director | DVP/OVRR | |
| Chiang Syin, Ph.D. | Supervisory Chemist | DMPQ/OCBQ | |
| Lori Austin-Hansbury | Senior Supervisory Regulator | DE/OBE | |
| Lisa Stockbridge | Supervisory Consumer Safety Officer | DCM/APLB/OCBQ | Yes |
| Patricia Holobaugh | Supervisory Consumer Safety Officer | DIS/OCBQ | |
| Keith Peden,, Ph.D. | Supervisory Microbiologist, | DVP/OVRR | Yes |
| Prakash Rath Ph.D. | Commissioner Fellow | OCS/OSAI | Yes |

1.0 BACKGROUND AND PURPOSE

BLA STN #125408/0, Sequence #0 was submitted by Novartis Vaccines and Diagnostics GmbH on October 31, 2011 and received by CBER on November 1, 2011. Payment was not received until November 22, 2011 and thus the review clock was reset to begin November 22, 2011.

The proposed indication is for active immunization of persons 18 years of age and older for the prevention of influenza disease caused by influenza virus subtypes A and B contained in the vaccine.

The purpose of this meeting is to discuss the completeness of the BLA submission and ensure it is acceptable to file.

2.0 DISCUSSION TOPICS

2.1 Filing Recommendations:

Clinical (Melisse Baylor) - acceptable

Statistical (Tammy Massie; Lihan Yan) – Clinical is acceptable; however, no subset analysis was performed on gender, age or race; Bioassays are acceptable; however, criterions have not been agreed upon

Product (Zhiping Ye) - acceptable

Toxicology (Nabil Al-Humadi) - acceptable

BiMo (Anthony Hawkins) - acceptable

Epidemiology (Damon Green) - acceptable

Facilities (Pankaj Amin) - acceptable

2.2 Milestones (Updated, milestones in gray have been completed)

Submitted: October 31, 2011

BLA Received: November 1, 2011; Fee Received **November 22, 2011**

Committee Assignment: November 15, 2011

First Committee Meeting: November 21, 2011

Filing Meeting: December 12, 2011

Filing Action: January 21, 2012

VRBPAC Determination: January 21, 2012

PeRC Determination: January 21, 2012

Deficiencies Identified: February 4, 2012

SWG Determination: April 20, 2012

First Draft Reviews Due: February 20, 2012 (March 21 for Stats and PhV)

Second Draft Reviews Due: May 15, 2012 (May 30 for Stats and PhV)

Final Reviews Due: July 14, 2012

Action Due: September 21, 2012

Action Package for Posting Due: September 21, 2012

2.3 Meetings (meetings in gray have been completed)

First Committee Meeting (via e-mail): November 16, 2011

Filing Meeting: December 12, 2011

Monthly Team Meetings: January 18, 2012 February 29, 2012
 May 7, 2012 June 11, 2012
 July 9, 2012 August 6, 2012

Mid-Cycle Review Meeting: April 9, 2012

PeRC: TBD

VRBPAC Planning: TBD

Safety Working Group (SWG): TBD

Labeling Meetings: TBD

2.4 Summary of Additional Action Items

- **Prelicensure Facility Inspection (or waiver) December 13, 2011**
- **Schedule Facility Inspection January 22, 2012**
- **Schedule BIMO Inspections February 4, 2012**
- Determine Consistency/Launch Lots February 20, 2012
- Facility Inspection Complete April 22, 2012
- BIMO Inspections Complete May 5, 2012
- PMC to FDAAA SWG August 4, 2012
- Labeling Target September 3, 2012

3.0 CONCLUSION

The BLA can be filed.

Additionally discussed:

- 1) An additional proprietary name review (PNR) for "Optaflu" is needed since the last time this name was reviewed and found acceptable was 2007. There are some concerns about the name now. The sponsor will be asked to submit a new PNR request.
- 2) Dr. Rajesh Gupta noted that there were ongoing discussions with Novartis regarding the suitability of using egg-based reagents for SRID testing of the MDCK cell-produced Optaflu.
- 3) The facility reviewer noted that an inspection of the Holly Springs, NC site would be waived since this site would be used only for testing and not product manufacture.

4) A BiMo inspection would probably not be needed since the pivotal efficacy trial site was already inspected during the Agriflu BLA efficacy trial supplement review (STN 125297/1).